Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 4/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326601 | 0.89 | NLRP3 (0.35) | IL1BSCN9AFPR2NLRP3PIM1 | |
| SCHEMBL29326790 | 0.88 | HPGDS (0.38) | IL1BSCN9AFPR2NLRP3HPGDS | |
| SCHEMBL29326505 | 0.85 | NLRP3 (0.49) | IL1BSCN9AFPR2NLRP3 | |
| SCHEMBL29326501 | 0.85 | NLRP3 (0.49) | IL1BSCN9AFPR2NLRP3 | |
| SCHEMBL29326604 | 0.82 | SCN9A (0.47) | IL1BSCN9AFPR2NLRP3HPGDS | |
| SCHEMBL29326508 | 0.79 | NLRP3 (0.48) | IL1BSCN9ANLRP3PIM1PIM2 | |
| SCHEMBL29326496 | 0.79 | NLRP3 (0.48) | IL1BSCN9ANLRP3PIM1PIM2 | |
| SCHEMBL29326512 | 0.79 | NLRP3 (0.47) | IL1BNLRP3 | |
| SCHEMBL26434544 | 0.76 | IL1B (0.47) | IL1BNLRP3 | |
| SCHEMBL29325902 | 0.76 | SCN9A (0.33) | SCN9APIM1PIM2PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | IL1B 11/4885SCN9A 3093/4885FPR2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.